Responses
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
775 Phase Ib/II Study of XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) combination in metastatic melanoma refractory to prior immune checkpoint Inhibitor therapy with and without CNS disease
Compose a Response to This Article
Other responses
No responses have been published for this article.
